Patriarchal Medicine: How Male-Centered Research Fails Women's Health

For decades, the architecture of medical science has been built around a single body: the male one. Women—more than half the world's population—have been treated as an afterthought, excluded from the clinical trials that determine how drugs work, how diseases progress, how lives are saved. The consequences are measured in preventable deaths.

A study published in The Lancet last September laid out the scale of the problem with clinical precision: at least 1.5 million women's deaths could be avoided through better cancer prevention and early detection strategies. The gap exists not because the science is impossible, but because women were never included in the research that might have prevented it. Mexican oncologist María Teresa Bourlon, one of the study's authors, traced the problem directly to patriarchal structures embedded in how medicine itself is practiced and studied.

The exclusion runs deeper than most people realize. Until the mid-1990s, cardiovascular research in many countries simply did not include women as subjects. They were removed from the equation entirely. Even now, despite clear biochemical, genetic, and physiological differences between male and female bodies, many major studies show little to no female representation. Carme Valls, an endocrinologist in Spain who spent more than two decades pushing for women's inclusion in clinical trials, has documented how this male-centered approach distorts everything downstream: diagnosis, treatment protocols, drug dosing, understanding of disease progression. When research is designed around men's bodies and men's symptoms, women's bodies become invisible—and invisible patients die without proper care.

The problem is especially acute in Latin America, where indigenous and Afro-descendant women face the worst health outcomes of all. They receive inadequate or nonexistent medical attention, suffer shorter life expectancies, and are systematically excluded from the research that might improve their chances. HIV prevention and treatment policies in Mexico, for instance, have been designed without women in mind, despite the fact that machismo and gender-based violence make women more vulnerable to infection. The research gap becomes a death gap.

Women now represent only about 30 percent of research authorships globally—a figure that grows even more dire in Latin America, where guidelines for female inclusion in biomedical research barely exist. Yet study after study shows that including women researchers in the design of clinical trials doesn't just mean more women get studied; it means the science itself improves. When research teams include women, sex becomes recognized as a meaningful biological variable. Researchers begin asking different questions: How does cancer affect women differently than men? What drug doses are appropriate for different bodies? The answers matter.

Even in animal research, the bias persists. Laboratory scientists long assumed that female rats were too hormonally unstable to produce reliable data, so they worked with males instead. A neuroscientist named Rebecca Shansky at Northeastern University tested this assumption in 2019 and found it backwards: female rats showed no greater variability than males. In some cases, males produced the most inconsistent results, driven by testosterone-fueled hierarchies among the animals. A foundational belief of experimental science turned out to be wrong—but only because someone finally looked.

Perhaps most telling is what remains unstudied: women's sexual and reproductive health. The clitoris, an organ central to female pleasure, remained absent from anatomical research for centuries. In 1998, the same year a scientist first mapped the organ's complete anatomy, Viagra arrived on pharmacy shelves. The timing is not coincidental. It reflects a medical system that has treated women's bodies as variations on a male template rather than as distinct biological entities deserving their own research attention. Menstruation, menopause, female sexuality itself—these remain shrouded in taboo and myth in the medical literature, starved of the rigorous investigation given to male sexual dysfunction.

The path forward requires more than good intentions. It requires policy: mandates for female researcher participation, requirements that women be included in clinical trial design, funding structures that reward sex-differentiated science. Latin America, where the research gaps are most severe, has barely begun this work. But the evidence is clear: when women are finally included in the research, when their bodies are studied as seriously as men's, medicine becomes better for everyone. The question is whether the system will change before another 1.5 million preventable deaths accumulate.